Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. (SENIOR)
Sponsor: Boston Scientific Corporation
A NA clinical study on Acute Coronary Syndrome and Silent Myocardial Ischemia, this trial is completed. The trial is conducted by Boston Scientific Corporation and has accumulated 9 data snapshots since 2014. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Feb 2024 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed · Phase: PHASE4 → NA
-
Jan 2021 — Feb 2024 [monthly]
Unknown Status PHASE4
▶ Show 4 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE4
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Recruiting PHASE4
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
- Ceric Sàrl
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alicante, Spain , Badalona, Spain , Barcelona, Spain , Boulogne-Billancourt, France , Brighton, United Kingdom , Brussels, Belgium , Craigavon, United Kingdom , Créteil, France , Fribourg, Switzerland and 28 more locations